Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I ready guys.....Give me a break ! Doesnt anybody see the potential here? Waiting to be noticed then we're good to go !!
Thanks Obi !!! And...Hello !!!! WTF !!! This is way undervalued isnt it ???? I'll keep quiet after this but.....
Just a few highlights....then I'll just sit back and wait...
BERWYN, Pa., Oct. 19 /PRNewswire-FirstCall/ -- Encorium Group, Inc. ENCO, a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.
The Company also announced that it has terminated previously announced negotiations for the sale of the Company's wholly-owned subsidiary Encorium OY to a clinical research organization based in the United States and will not pursue a sale of the Company or Encorium OY at this time. Given the Company's recent successes with respect to its strategy to grow into the world's leading vaccine franchise, including the recently announced $8.7 million of new business contract wins and the selection by a major pharmaceutical company for participation in a swine flu vaccine program, together with the investment announced today, the Company believes it is well positioned to win future contracts in the vaccine and oncology fields. As a result, the Company believes stockholder value will be maximized by moving ahead independently, while continuing to focus on clinical vaccine development.
Dr. Kai Lindevall, executive chairman stated, “We are very pleased that we were able to close this financing to shore up our balance sheet and provide the Company with additional working capital. Our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long term potential we have to grow into a leading vaccine franchise with expertise in pre-clinical support, regulatory consultancy and strategic trial planning. We believe these developments will position us to move ahead independently and are in the best interest of all stockholders.”
Encorium today announced the signing of approximately $8.7 million of new business contracts, including selection by a major pharmaceutical company for participation in a swine flu vaccine program.
"Dr. Kai Lindevall, executive chairman stated, “We are delighted to be able to announce these new business awards, despite a very challenging market environment. Our experience and capabilities in the vaccine field have been of paramount importance in our success. We are very proud of being the selected partner for one of the frontline clinical development programs for the swine flu vaccine. In addition, we were also recently entrusted with a avian flue vaccine, as well as other vaccine development programs having, in the aggregate, approximately 12,000 patient subjects. We believe our participation in these studies exemplifies the level of trust and respect that large vaccine companies have in our vaccine expertise and clinical operations."
“We believe Encorium has developed into one of the strongest medium sized clinical research organizations with expertise in the field of clinical vaccine development. Our recent success in the vaccine field has been substantial, with revenues from vaccine trials increasing by 150% in 2009 versus 2008. As an acknowledgement of our achievements, in April 2009, Encorium was nominated as a finalist for the Second Annual Vaccine Industry Excellence Award."
Hello !!!! WTF !!! This is way undervalued isnt it ????
Just a few highlights....then I'll just sit back and wait...
BERWYN, Pa., Oct. 19 /PRNewswire-FirstCall/ -- Encorium Group, Inc. ENCO, a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.
The Company also announced that it has terminated previously announced negotiations for the sale of the Company's wholly-owned subsidiary Encorium OY to a clinical research organization based in the United States and will not pursue a sale of the Company or Encorium OY at this time. Given the Company's recent successes with respect to its strategy to grow into the world's leading vaccine franchise, including the recently announced $8.7 million of new business contract wins and the selection by a major pharmaceutical company for participation in a swine flu vaccine program, together with the investment announced today, the Company believes it is well positioned to win future contracts in the vaccine and oncology fields. As a result, the Company believes stockholder value will be maximized by moving ahead independently, while continuing to focus on clinical vaccine development.
Dr. Kai Lindevall, executive chairman stated, “We are very pleased that we were able to close this financing to shore up our balance sheet and provide the Company with additional working capital. Our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long term potential we have to grow into a leading vaccine franchise with expertise in pre-clinical support, regulatory consultancy and strategic trial planning. We believe these developments will position us to move ahead independently and are in the best interest of all stockholders.”
Encorium today announced the signing of approximately $8.7 million of new business contracts, including selection by a major pharmaceutical company for participation in a swine flu vaccine program.
"Dr. Kai Lindevall, executive chairman stated, “We are delighted to be able to announce these new business awards, despite a very challenging market environment. Our experience and capabilities in the vaccine field have been of paramount importance in our success. We are very proud of being the selected partner for one of the frontline clinical development programs for the swine flu vaccine. In addition, we were also recently entrusted with a avian flue vaccine, as well as other vaccine development programs having, in the aggregate, approximately 12,000 patient subjects. We believe our participation in these studies exemplifies the level of trust and respect that large vaccine companies have in our vaccine expertise and clinical operations."
“We believe Encorium has developed into one of the strongest medium sized clinical research organizations with expertise in the field of clinical vaccine development. Our recent success in the vaccine field has been substantial, with revenues from vaccine trials increasing by 150% in 2009 versus 2008. As an acknowledgement of our achievements, in April 2009, Encorium was nominated as a finalist for the Second Annual Vaccine Industry Excellence Award."
I like this one ....
"Rather than simply looking to acquire possible reserves by acquiring enormous but unqualified land prospects, Morgan Creek Energy is building a strategic portfolio and strong operating infrastructure designed to deliver a balance between risk/reward and a path to immediate revenue"
"The Company is has acquired significant land positions in two project areas and plans to be able to initiate drilling operations in the last quarter of 2009. Follow-on and development drilling programs are set to begin after thoroughly testing the primary target zones in each wellbore. Wells will be tied in and put on production as soon as market access can be acquired and flowlines laid to tie in points."
ENCO I'm in under .40 Obi !!! You in?
Just wait....It going to move up.... I'm in ......The price down is a joke..... IMO they cant keep this down.... Good luck !
Sorry !!! LOL.... Nice pick of the day....Good job !!!
NWURF..... You have a chart for that one Eco....when you get a minute. Been watching that one awhile.....starting to move.
I got this so far..... something coming out today
"Federal drug agents won't pursue pot-smoking patients or their sanctioned suppliers in states that allow medical marijuana, under new legal guidelines to be issued Monday by the Obama administration."
"
"The new policy is a significant departure from the Bush administration, which insisted it would continue to enforce federal anti-pot laws regardless of state codes."
Obi !!!! oopps ! Did I miss something on your possible bucket list entry????? RGCI up 20+ percent !!!!! Dang it !
Why isnt this at the 1.00 price? Or at least the high .80's ? These guys have been moving forward like clock work...... way over due IMO
I'm not sure.. that article just hit the wire 10 minutes ago ! The first run was from something Obama said I think..... Its a matter of time..... some big money players are going to think long term at a year or 2 this thing could turn a hundred grand into a mil......
Check it out investor !!! Word is getting out !
http://www.worldmarketmedia.com/779/section.aspx/454/post/cbis-cannabis-science-inc-otcbb-053-12m-marketcap
PPTO.....your having fun today !!! Good morning !! Thanks for the sugar post :) !
oops!!! Ok then forget my shares !!!! The main thing today is the volume......word is getting out buddy !!!
It cant stay that way forever...... I may jump in a few hundred and sit a week or two with it......Watching right now......
EOD buy at the ask investor !! I'll sell you mine at 1.10 !!!!!
Good byeeeeeeee investooooooor byeeeeeeeeeeee LOL !!!
Im buying a few more......whats up with this dip?
Hell no ! I aint selling you nothing pal !!! haha !!! The ask is .59 buddy......You aint getting in cheaper ! ask was .60 just a second ago....... .70 by EOD !!!!! LOL !!!!
Obi ENCO... SEC 8k Good !!! PR Good !!! Price down ! Buy at .40 !!!!!!! ??????????????
This one is on a lot of lists !!!! IMO should sit at .22 before PR.......just hasnt made it yet... Good place to sit before the run ?
This one is sweet ! Lets not forget..... This is gunna help a lot of people...... My back pain just may be getting better soon investor !!!!!! :)
Nice open ! Look at the volume today !
Looks like the time to jump in ENCO.... ask .45 right now ! Bucket list looks green today Obi !
Good morning !!!! I woke up a bit late ! To much reading last night ! Looks to be a green day !!!! Good luck all !!!!
Today may be the day...... Big gains possible...... "Just gotta a feeling about this one" !
Qmin.... I'm looking at that one now..... Hmmmmmm get back to you Monday !!!
NGHI 8k and 10Q has a few concerns but no mention of any defaults on loans or any talk of dilution...... It will need to raise capital but thats expected... then it looks like they raised capital by a PPO........ IMO worth a try just keep a eye on it....Whats your guess Eco ???
A few quotes from 10Q........Letter to investor & "going concern"
[Investor name and address]
Ladies and Gentlemen:
“You have previously entered into a Subscription Agreement (the “Agreement”) with Nevada Gold Holdings, Inc., a Nevada Corporation (the
“Company”), in connection with the private placement offering (the “Offering”) of a minimum of 4,000,000 and a maximum of 8,000,000 units
of securities (the “PPO Units”) issued by the Company, at a purchase price of $0.25 per PPO Unit. Each PPO Unit consists of (i) one share of
the Company’s common stock, par value $0.001 per share (“Common Stock”), and (ii) a warrant representing the right to purchase one share of
Common Stock, exercisable for a period of five years at an exercise price of $0.50 per whole share; and in the event the Offering is
oversubscribed, the Company may, in its discretion, sell up to 1,000,000 additional Units at the same purchase price per Unit.
The Company desires to modify the terms of the Agreement to provide that the minimum size of the Offering shall be 2,000,000 PPO
Units. All other terms of the Agreement and the Offering will remain unchanged. If you are in agreement, please sign, date and return to us as
indicated below a copy of this letter. By so doing, you also confirm the continued accuracy of the information in the Investor Certification
submitted by you with your subscription agreement.
Please send a signed copy of this letter to:
Gottbetter & Partners, LLP”
“The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to
a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has
not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability
of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it
becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. These factors raise substantial
doubt about the Company’s ability to continue as a going concern.
In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to
obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its minimal
operating expenses and seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be
successful in accomplishing any of its plans.
The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the
preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements
do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.”
Well…. RGCI..Looks like a strong buy rating from a few sites on this one Obi…The measure of relative price change and consistency is very high…. that’s a positive….Shares are being heavily sold by financial institutions… But ! That’s not such a big deal…..take a look at the list of Funds that arent selling … 29% Institutional Ownership….. But it looks like a reverse split coming soon also….I saw the words Dilute on page 42 Obi ! LOL I wish they gave more updates following the last 10Q !!!!! Its guess work as to the loan agreement problem…..50-50 chance here Obi…IMO this may be as high as she goes….
The last 10Q 8-7-09 filing showed that in the event that a audit was done and it contained the words “on going concern” the company would be in default of its loan with Bank of America… Page 15 of the 10Q…… “ As of April 30, 2009, the 30-day period expired, and the Company’s inability to cure the default constituted an Event
of Default under the terms of the agreement. Due to the Event of Default, the lenders could require that outstanding borrowings under the credit agreement be accelerated to currently payable.
Now further down the 10Q as of June 30th no solution has been made but maybe because revenue is increasing the banks may be working with RGCI ?????
Page 23 10Q…“We have continued to develop our Interactive initiative in 2009, which focuses on generating revenues through our stations’ websites. Our
integrated selling effort combines the sale of our Interactive products with sales of our traditional broadcasting spots. Net revenue provided
by our Interactive initiatives during the first six months of 2009 increased by approximately 50% over the comparable 2008 period, and we
anticipate that our economic benefits from this revenue source will increase through the remainder of 2009 and beyond. In addition, our
2009 focus is also directed towards developing Interactive revenue from new sources that are not affiliated with our radio stations. While we
do not anticipate that this revenue will be material in 2009, we expect that it will increase in future years.
Page 42 10Q on the split….
“If the Company implements the reverse stock split, such action could have a future dilutive effect on the Company’s stockholders and/or a
potential anti-takeover effect on the Company.
If implemented, the proposed reverse stock split will reduce the number of the Company’s outstanding shares of common stock but will not
reduce the number of authorized shares of the Company’s common stock. As a result, this will increase significantly the ability of the
Company’s Board of Directors to issue authorized and unissued shares without further stockholder action. The issuance in the future of such
additional authorized shares may have the effect of diluting the earnings per share and book value per share, as well as the stock ownership and
voting rights, of the currently outstanding shares of common stock.”
Good luck James... Im going to sit that one out...but I wish you the best .... Next week we both have many to watch were both in !!!!
I understand....Im going to sit on this awhile... not a large position ...seems to have support at the .05 - .06 range and tends to pop to .15 or so..... If it stays sideways to long I'll probably find some where else to go thats for sure.....
Good luck this week !
NGHI ...... You may have something here Buddy !!! 52 week low .10 high .62 I love bottom feeding you know that !!!! LoL !!!! and I nice quote from CEO and Chief Geologist ……..IMO not in this one YET......But watching....Hey!!...a friend just told me NGHI sometimes does PR pumpers so IMO ride the high and get out.....you know buy dips sell highs....but still may turn out to be a real producer long term ok?
“Tempo is one of the best exploration properties I have seen in my 35-year Nevada career, and I look forward to commencing site construction and drilling shortly. Almost all of the existing 160 holes on the property have been drilled very shallow, and based on my current geological models, I believe that the right host rocks for a large deposit are deeper, and I expect to utilize this drilling program to confirm the need for a much larger drilling project in the future,” commented Dave Mathewson.
The property was originally identified and staked by well-known, successful Nevada prospector, Lyle Campbell, in 1968, and a mineral lease was assigned to Nevada Gold Holdings in December, 2008. Today, the property’s land position consists of 206 contiguous unpatented lode claims, totaling approximately 4000 acres or 6.3 square miles. Tempo’s land position effectively controls a district-scale exploration opportunity and has ingredients that the Company believes suggest potential for several large, 1 million ounce plus, deposit discoveries.
CBIS..... a lot of talk going on with this one..... Seems CBIS could help a lot of people.... its not just a joke to legalize pot smoking.... its serious to help in the drug industry......IMO..... its worth doing some research... I'm in this one as a matter of fact.....
Endocannabinoids are marijuana-like compounds that are produced by most animals, including all vertebrates. Quite surprisingly, the endocannabinoids system has an all-pervasive role in maintaining homeostasis (biochemical balance). All living creatures suffer from a common biochemical imbalance, we are all aging. Today, in developed countries, most people suffer and die from age-related illnesses including cardiovascular diseases, autoimmune diseases, neurological disorders, and cancers. Modern science from an abundance of peer-reviewed publications indicates that stimulating the endocannabinoid system benefits all of these conditions.
We understand what patients need and want. As a result, the Company offers the savvy investor a novel opportunity to participate in producing groundbreaking products that will impact some of the most important medical concerns of our times. In addition to targeting the billion dollars a year pain management industry, the Company is uniquely positioned to develop products for high blood pressure, cancer, HIV, and the bird flu.
Cannabis Science is in a unique position to pursue the development of blood pressure and cancer medications. The endocannabinoid system normally regulates blood pressure through its capacity to dilate blood vessels and reduce adrenergic stimuli. Additionally, there is a developing body of evidence that shows both the tumor killing properties of endo- and phyto- cannabinoids, and their ability to inhibit metastasis in a variety of cancers.
Cannabis Science works with world authorities on phytocannabinoid science developing cannabis-based therapeutics that will holistically promote health by restoring biochemical balance. By adhering to underlying scientific principles, the Company will manipulate all-pervasive phytocannabinoid processes to target a variety of disparate illnesses.
An emergent global threat is that the bird flu, a strain (H5N1) of influenza A, will evolve to infect human beings. The typical yearly variation in flu strains has been an ongoing challenge and concern to researchers developing preventative and therapeutic products. The high degree of variability found in the influenza A virus is an intrinsic property of the virus’s chromosomal structure and how it replicates. Overcoming the difficulties encountered in this field take on even greater importance with the threat of the bird flu jumping species bird into the human population.
The bird flu differs from other strains by its enhanced capacity to kill infected individuals. The common cause of death with this strain is that patients developed adult respiratory distress syndrome (ARDS). ARDS is in excess inflammatory response that leads to apoptosis and organ failure. The Company’s approach will mimic how the human body uses endocannabinoids to regulate immune activity and cell survival.
The magnitude of the bird flu threat is so great that positive results from this arm of our research would greatly facilitate the acceptance of our cannabis-based pharmaceuticals. There should be highly profitable additional applications that result.
More recently, revolutionary scientific breakthroughs in understanding the HIV infective and developmental processes have been discovered that will lead to entirely new therapeutic approaches.
Cannabis Science is uniquely positioned to explore insights that indicate an intrinsic link between novel cancer and HIV technologies and the cannabinoid system. Published experiments by a leading AIDS researcher, Dr. Donald Abrams, suggest that counter to conventional wisdom, smoked marijuana does not result in an increased HIV viral load. In fact, there were suggestions of a reduced viral load. We expect to show that our pharmaceuticals will enhance biochemical markers that are indicative of a successful HIV therapy based on recent paradigm breaking discoveries.
Overall, our product development will follow two parallel paths. We will create pharmaceuticals with and without psychoactive properties. Both of these lines will have numerous health benefits for treating illnesses and for general health maintenance. Both psycho and non-psychoactive products with demonstrated therapeutic efficacy for these globally important illnesses will facilitate entry first into the Canadian marketplace. Proven efficacy in the Canadian market should then open the US and global markets.
Try this link and see if it works..... http://moneycentral.msn.com/investor/sec/filing.asp?Symbol=NGHI
James !! Every time I get to a new pick you've already been here !!!!! LOl !!!! Whats you take on this one???? Seems to be ready????? IMO
James....last 10Q filed looked pretty good.....Did you read the last 8k ? Am I mistaken or did it look like a bunch of shares being bought by accredited investors????????
Lets make that clear.......No one go by my DD LOL !!!! But I cant post a few "Heads up" to go along with these charts...
Speaking of DD..... ORS is trading at 2x earnings.... good revenue and is doing fairly well through the economic down turn.....it has cut costs and expects revenue to increase by 15%....... Was wondering what your charts say..... Ive noticed from the past several weeks a match with charts and a good 8k or 10Q filing brings very good gains vs a stock with only a good filing or chart..... Hmmmmmm....
Sure ! Im not good at your band readings but I can give you a little DD to match up with your charts .... ?????
Yes......and look at GST ! I sold that at what would be around 3.50 a share......its past $5 now I think !!! You may be right James....